LONG-TERM OUTCOMES FOLLOWING A SWITCH FROM ORIGINATOR ADALIMUMAB TO THE BIOSIMILAR SB5 (IMRALDI) IN IBD

Heather Dolby  1     Nikolas Plevris  1     Laura Lucaciu  1     Caitlin Rees  1     Mathew Lyons  1     Spyridon Siakavellas  1     Nathan Constantine-Cook  2     Philip Jenkinson  1     Shanna Su  1     Claire O'Hare  1     Laura Kirkpatrick  1     Lynne Merchant  1     Gareth R Jones  2     Charlie W. Lees  2     Ian D Arnott  1     colin noble  1    
1 Western General Hospital, Edinburgh, United Kingdom
2 University of Edinburgh, Edinburgh, United Kingdom

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing